

TOS-125-USA-PCT

REMARKS

The specification has been amended to show the relationship to the parent application, as well as to correct several typographical errors previously discussed with Examiner Berman in the interview held in the parent application on November 17, 1999.

It is respectfully submitted that this application is now in condition for examination on the merits and early action and allowance thereof is accordingly respectfully requested.

Respectfully submitted,

TOWNSEND & BANTA



Donald E. Townsend
Reg. No. 22,069

Donald E. Townsend, Jr.

Donald E. Townsend, Jr.
Reg. No. 43,198

Date: November 6, 2002

TOWNSEND & BANTA
1225 Eye Street, N.W.
Suite 500, #50028
Washington, D.C. 20005
(202) 682-4727

TOS-125-USA-PCT

On page 25, last line, to page 6, line 10, please replace the original paragraph therein with the amended paragraph as follows:

--The results are shown in FIG. 3. In FIG. 3, the vertical axis represents the intensity of the ultraweak chemiluminescence [(a relative value (%) assuming the [blank] normal value without anything applied to be 100)] and along the horizontal axis are the essential ingredients of the liniment composition for preventing environmental stress of the present invention for which the testing was conducted. Among these essential ingredients, the vitamin C derivative refers to the aforementioned L-ascorbic acid phosphate (magnesium).--

TOS-125-USA-PCT

MARKED-UP VERSIONS OF AMENDED PORTIONS OF THE SPECIFICATION:

On page 21, please replace the original third paragraph therein with the amended paragraph as follows:

--After the culture was completed, the medium was removed and replaced with PBS (-) and the ultraweak chemiluminescence from the aforementioned human fibroblast cells adhered to the bottom of the Petri dish was measured for 10 minutes using a chemiluminescence detector (model CLD-110 from Tohoku Electronic Industries Co., Ltd.). The number of photoelectrons generated during this time was converted to an electric voltage to obtain the [blank] normal value of the ultraweak chemiluminescence.--

On page 23, please replace the original second paragraph therein with the amended paragraph as follows:

--An 1.0 wt% aqueous solution of each of the 1) α -tocopherol, 2) β -carotene, 3) thiotaurine (from Sogo Pharmaceutical Co., Ltd.), 4) hypotaurine (from Sogo Pharmaceutical Co., Ltd.), 5) glutathione, 6) tannin, 7) vitamin C derivative [](L-ascorbic acid phosphate (magnesium)[]), 8) thiotaurine + malic acid, 9) hypotaurine + malic acid and 10) glutathione + malic acid (when combined with malic acid, 1.0 wt% of malic acid was contained as well as 1.0 wt% of the antioxidant) was applied on the medial aspect of a human forearm. For each of these, the [blank] normal value of the corneum moisture content was measured. For the controls, "the group with no drug applied" and "the non-exposure group", which was not exposed to tobacco smoke or exhaust gas, were used.--